Viewing Study NCT00129168

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:26 PM
Ignite Modification Date: 2026-02-01 @ 11:22 PM
Study NCT ID: NCT00129168
Status: COMPLETED
Last Update Posted: 2008-04-01
First Post: 2005-08-09
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Sponsor: Kanisa Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Leukemia, Myeloid View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Leukemia, Myeloid View
None Relapse View
None Chemotherapy View
None Zosuquidar View
None Daunorubicin View
None Cytarabine View
None Acute View
None AML View
None Adult AML View